Global biopharmaceutical firm AbbVie opens facility in Singapore

Its total investment is worth over $400M.

AbbVie, a global biopharmaceutical company listed at New York Stock Exchange, today strengthened its manufacturing capabilities by opening the small molecule active pharmaceutical ingredient (API) facility of its Singapore manufacturing site.

This facility supports the growth of AbbVie's oncology and women's health pipeline and reflects progress from AbbVie's two previous announcements for manufacturing investment in Asia in 2014.

The new 120,000 square-meter site – located in the Tuas Biomedical Park – is AbbVie's first manufacturing facility in Asia and will also include a biologics manufacturing facility that is expected to be fully operational by the end of 2018.

Combined, the API and biologics facilities represent a $320 million (more than S$400 million ) investment in Singapore that will employ more than 250 new employees, the majority of whom will be hired locally in Singapore , including skilled positions across manufacturing, technical operations, administration, quality, information technology and supply chain.

AbbVie's manufacturing network now includes 13 locations across the United States , Europe , Asia and Puerto Rico , as well as strategic partnerships with third-party manufacturers.